logo
logo

Synthace Raises $35M To Expand Access To Its Revolutionary R&Amp;D Technology For Life Changing Research

Nov 16, 2021•over 3 years ago

Amount Raised

$35 Million

London

Description

Synthace, the first life sciences software company to enable scientists to automate biology experimentation and insight sharing in a unified, global R&D environment today announced it raised $35 million in Series C funding. The investment will fuel commercial and go-to-market (GTM) growth as Synthace continues to radically reinvent the full value chain of life sciences R&D. The company also plans to expand its senior leadership team in the U.S., with new vice presidents of marketing and sales joining the U.S.-based CEO.

Company Information

Company

Synthace

Location

London, Ontario, Canada

About

Synthace is a life sciences software company enabling life science the way it should be done. Delivering a life sciences R&D cloud to scientists who want to innovate faster, the Synthace platform seamlessly automates experimentation and insight sharing so that scientists can focus on asking the most impactful questions to unlock the true potential of biology. Top global pharmaceuticals, high-growth biotech companies, leading CDMOs, and innovators in artificial intelligence all turn to Synthace to discover solutions to humanity’s hardest problems. To learn more about how Synthace is transforming life sciences for a better future visit www.synthace.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech